Business News • PR NewsWire • CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency

CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency

CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency

TOKYO, Sept. 27, 2013 /PRNewswire/ -- CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary...

View More : http://www.prnewswire.com/news-releases/csl-behring-gains-approval-to-license-hizentra-in-japan-for-the-treatment-of-pri...

Releted News by prnewswire

UN IPCC Climate Report Untrustworthy

2014 MAZDA6 EARNS 'ADVANCED' RATING BY INSURANCE INSTITUTE FOR HIGHWAY SAFETY